Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target

Compare

568 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RYTM Analyst Ratings

Strong Buy

14 Buy

1 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Rhythm

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RYTM Stock 12 Month Forecast

Average Price Target

$138.62

▲(23.27% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Rhythm Pharmaceuticals in the last 3 months. The average price target is $138.62 with a high forecast of $167.00 and a low forecast of $110.00. The average price target represents a 23.27% change from the last price of $112.45.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"49":"$49","168":"$168","78.75":"$78.8","108.5":"$108.5","138.25":"$138.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":167,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$167.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":138.62,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$138.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$110.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[49,78.75,108.5,138.25,168],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,105.04,109.80615384615385,114.5723076923077,119.33846153846154,124.10461538461539,128.87076923076924,133.6369230769231,138.40307692307692,143.16923076923078,147.93538461538463,152.70153846153846,157.46769230769232,162.23384615384617,{"y":167,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,105.04,107.62307692307692,110.20615384615385,112.78923076923077,115.3723076923077,117.95538461538462,120.53846153846155,123.12153846153846,125.7046153846154,128.2876923076923,130.87076923076924,133.45384615384617,136.03692307692307,{"y":138.62,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,105.04,105.42153846153846,105.80307692307693,106.18461538461538,106.56615384615385,106.94769230769231,107.32923076923078,107.71076923076923,108.0923076923077,108.47384615384615,108.85538461538462,109.23692307692308,109.61846153846153,{"y":110,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":60.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.98,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.43,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.21,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.76,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.04,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$167.00

Average Price Target$138.62

Lowest Price Target$110.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Seamus Fernandez

Guggenheim

$120→$140

Buy

24.50%

Upside

Reiterated

12/16/25

Rhythm Pharmaceuticals price target raised to $140 from $120 at GuggenheimRhythm Pharmaceuticals price target raised to $140 from $120 at Guggenheim

Faisal Khurshid

Leerink Partners

$135→$142

Buy

26.28%

Upside

Reiterated

12/15/25

Leerink Partners Sticks to Their Buy Rating for Rhythm Pharmaceuticals (RYTM)

Jonathan Wolleben

Citizens JMP

$141→$167

Buy

48.51%

Upside

Reiterated

12/12/25

Rhythm Pharmaceuticals price target raised to $167 from $141 at CitizensRhythm Pharmaceuticals price target raised to $167 from $141 at Citizens

Derek Archila

Wells Fargo

$129

Buy

14.72%

Upside

Reiterated

12/12/25

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Rhythm Pharmaceuticals (NASDAQ: RYTM)

Corinne Johnson

Goldman Sachs

$141→$157

Buy

39.62%

Upside

Reiterated

12/12/25

Goldman Sachs Remains a Buy on Rhythm Pharmaceuticals (RYTM)

Michael Ulz

Morgan Stanley

$129→$150

Buy

33.39%

Upside

Reiterated

12/12/25

Promising Phase 2 Results for Rhythm Pharmaceuticals' Setmelanotide in Prader-Willi Syndrome Boost Buy Rating

Joseph Stringer

Needham

$120→$145

Buy

28.95%

Upside

Reiterated

12/11/25

Positive Phase 2 Trial Results Boost Rhythm Pharmaceuticals' Outlook and Price Target

Whitney Ijem

Canaccord Genuity

$114→$141

Buy

25.39%

Upside

Reiterated

12/11/25

Canaccord Genuity Remains a Buy on Rhythm Pharmaceuticals (RYTM)

Paul Matteis

Stifel Nicolaus

Buy

―

Reiterated

12/11/25

Promising Clinical Results and Market Potential Drive Buy Rating for Rhythm Pharmaceuticals

Phil Nadeau

TD Cowen

$120

Buy

6.71%

Upside

Reiterated

12/11/25

TD Cowen Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)

Tazeen Ahmad

Bank of America Securities

$127→$140

Buy

24.50%

Upside

Reiterated

12/11/25

Rhythm Pharmaceuticals price target raised to $140 from $127 at BofARhythm Pharmaceuticals price target raised to $140 from $127 at BofA

Samantha Semenkow

Citi

$136

Buy

20.94%

Upside

Initiated

11/25/25

Rhythm Pharmaceuticals initiated with a Buy at CitiRhythm Pharmaceuticals initiated with a Buy at Citi

Dennis Ding

Jefferies

$125

Buy

11.16%

Upside

Reiterated

11/13/25

Jefferies Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)

Ram Selvaraju

H.C. Wainwright

$110

Buy

-2.18%

Downside

Reiterated

11/10/25

Positive Outlook for Rhythm Pharmaceuticals Despite FDA Review Delay and Financial Shortfall

Leland Gershell

Oppenheimer

Hold

―

Downgraded

11/04/25

Oppenheimer downgrades Rhythm Pharmaceuticals (RYTM) to a Hold

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Seamus Fernandez

Guggenheim

$120→$140

Buy

24.50%

Upside

Reiterated

12/16/25

Rhythm Pharmaceuticals price target raised to $140 from $120 at GuggenheimRhythm Pharmaceuticals price target raised to $140 from $120 at Guggenheim

Faisal Khurshid

Leerink Partners

$135→$142

Buy

26.28%

Upside

Reiterated

12/15/25

Leerink Partners Sticks to Their Buy Rating for Rhythm Pharmaceuticals (RYTM)

Jonathan Wolleben

Citizens JMP

$141→$167

Buy

48.51%

Upside

Reiterated

12/12/25

Rhythm Pharmaceuticals price target raised to $167 from $141 at CitizensRhythm Pharmaceuticals price target raised to $167 from $141 at Citizens

Derek Archila

Wells Fargo

$129

Buy

14.72%

Upside

Reiterated

12/12/25

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Rhythm Pharmaceuticals (NASDAQ: RYTM)

Corinne Johnson

Goldman Sachs

$141→$157

Buy

39.62%

Upside

Reiterated

12/12/25

Goldman Sachs Remains a Buy on Rhythm Pharmaceuticals (RYTM)

Michael Ulz

Morgan Stanley

$129→$150

Buy

33.39%

Upside

Reiterated

12/12/25

Promising Phase 2 Results for Rhythm Pharmaceuticals' Setmelanotide in Prader-Willi Syndrome Boost Buy Rating

Joseph Stringer

Needham

$120→$145

Buy

28.95%

Upside

Reiterated

12/11/25

Positive Phase 2 Trial Results Boost Rhythm Pharmaceuticals' Outlook and Price Target

Whitney Ijem

Canaccord Genuity

$114→$141

Buy

25.39%

Upside

Reiterated

12/11/25

Canaccord Genuity Remains a Buy on Rhythm Pharmaceuticals (RYTM)

Paul Matteis

Stifel Nicolaus

Buy

―

Reiterated

12/11/25

Promising Clinical Results and Market Potential Drive Buy Rating for Rhythm Pharmaceuticals

Phil Nadeau

TD Cowen

$120

Buy

6.71%

Upside

Reiterated

12/11/25

TD Cowen Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)

Tazeen Ahmad

Bank of America Securities

$127→$140

Buy

24.50%

Upside

Reiterated

12/11/25

Rhythm Pharmaceuticals price target raised to $140 from $127 at BofARhythm Pharmaceuticals price target raised to $140 from $127 at BofA

Samantha Semenkow

Citi

$136

Buy

20.94%

Upside

Initiated

11/25/25

Rhythm Pharmaceuticals initiated with a Buy at CitiRhythm Pharmaceuticals initiated with a Buy at Citi

Dennis Ding

Jefferies

$125

Buy

11.16%

Upside

Reiterated

11/13/25

Jefferies Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)

Ram Selvaraju

H.C. Wainwright

$110

Buy

-2.18%

Downside

Reiterated

11/10/25

Positive Outlook for Rhythm Pharmaceuticals Despite FDA Review Delay and Financial Shortfall

Leland Gershell

Oppenheimer

Hold

―

Downgraded

11/04/25

Oppenheimer downgrades Rhythm Pharmaceuticals (RYTM) to a Hold

Stocks with the Highest Top Analyst Consensus in the Sector

Find stocks in the sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Rhythm Pharmaceuticals

1 Month

xxx

Success Rate

16/20 ratings generated profit

Average Return

+8.01%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +8.01% per trade.

3 Months

xxx

Success Rate

16/20 ratings generated profit

Average Return

+19.37%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +19.37% per trade.

1 Year

Whitney IjemCanaccord Genuity

Success Rate

19/20 ratings generated profit

Average Return

+78.14%

reiterated a buy rating 8 days ago

Copying Whitney Ijem's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +78.14% per trade.

2 Years

xxx

Success Rate

19/20 ratings generated profit

Average Return

+133.03%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 95.00% of your transactions generating a profit, with an average return of +133.03% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RYTM Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RYTM has received 22 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. RYTM average Analyst price target in the past 3 months is 138.62.

Each month's total comprises the sum of three months' worth of ratings.

RYTM Financial Forecast

RYTM Earnings Forecast

Next quarter’s earnings estimate for RYTM is -$0.82 with a range of -$0.96 to -$0.69. The previous quarter’s EPS was -$0.82. RYTM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year RYTM has Performed in-line its overall industry.

RYTM Sales Forecast

Next quarter’s sales forecast for RYTM is $55.26M with a range of $52.00M to $57.50M. The previous quarter’s sales results were $51.30M. RYTM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year RYTM has Performed in-line its overall industry.

RYTM Stock Forecast FAQ

What is RYTM’s average 12-month price target, according to analysts?

Based on analyst ratings, Rhythm Pharmaceuticals Inc’s 12-month average price target is 138.62.

What is RYTM’s upside potential, based on the analysts’ average price target?

Rhythm Pharmaceuticals Inc has 23.27% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RYTM a Buy, Sell or Hold?

Rhythm Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 14 buy ratings, 1 hold ratings and 0 sell ratings.

What is Rhythm Pharmaceuticals Inc’s price target?

The average price target for Rhythm Pharmaceuticals Inc is 138.62. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $167.00 ,the lowest forecast is $110.00. The average price target represents 23.27% Increase from the current price of $112.45.

What do analysts say about Rhythm Pharmaceuticals Inc?

Rhythm Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of RYTM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target

RYTM Analyst Ratings

RYTM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Rhythm Pharmaceuticals

RYTM Analyst Recommendation Trends

RYTM Financial Forecast

RYTM Earnings Forecast

RYTM Sales Forecast

RYTM Stock Forecast FAQ

Detailed List of Analyst Forecasts